Search
Close this search box.

Evaluation of next generation sequencing (NGS) as a rapid, alternative assay for in vivo and in vitro adventitious virus testing for vaccine safety

This project proposes to: 1) compare NGS with currently used in vivo animal assay and in vitro cell culture and PCR assays; and 2) develop a well-qualified reference virus database (RVDB II)
Categories
Proteins/ Antibodies
Vaccines
Assays
Project status
100% Completed

Industry Need

  • Next generation sequencing (NGS) is a powerful tool to broadly and rapidly detect adventitious viruses for enhancing safety and product development of vaccines and other biologics. 
  • While ongoing efforts have demonstrated feasibility for standardization and validation of this complex technology for adventitious virus detection, the industry could benefit from enhanced confidence in the use of NGS.  

 

Solution

The FDA, along with GSK, MilliporeSigma, and the University of Delaware, will:  

  1. Compare NGS with currently used in vivo animal assay and in vitro cell culture and PCR assays to determine the applications of NGS as alternative assays 
  2. Develop a well-qualified reference virus database (RVDB II) that will facilitate specific detection of viruses for accurate interpretation of NGS data for adventitious virus detection. 


Outcomes and Impacts

Reduce the use of animals for adventitious agent testing

Streamline and standardize bioinformatic analysis pipelines

Decrease cost and time required for adventitious virus testing, helping to facilitate more rapid product development

Assist regulatory agencies with decision-making and policy development regarding the use of NGS for replacing the in vivo animal assays and for replacing or supplementing the in vitro assays currently used for virus testing

Updates, Related Publications, and Deliverables

  • Login to the NIIMBL member portal for access to project updates, related publications, and deliverables. 

Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.

Project Lead

Federal Stakeholder: Food and Drug Administration

Federal Stakeholder: Food and Drug Administration

Participating Organizations

GlaxoSmithKline, LLC

GlaxoSmithKline, LLC

MilliporeSigma/EMD Serono

MilliporeSigma/EMD Serono

University of Delaware

University of Delaware

Join Our Mailing List

MailChimp NIIMBL Mailing List Signup
Organization Type
How did you first hear about NIIMBL?